Skip to main content
. 2021 Apr 28;12(5):662. doi: 10.3390/genes12050662

Figure 3.

Figure 3

In KRAS-mutated cancer cells, treatment with either KRASG12C inhibitors or MEK inhibitors causes rebound RTK signaling leading to therapeutic resistance. Inhibition of proximal RTK signaling using inhibitors of the common proximal RTK signaling intermediates SHP2 or SOS1 can potentially limit resistance to oncogene-targeted therapies, thereby significantly prolonging the initial window of therapeutic efficacy.